The next-generation KRAS G12C inhibitor divarasib represents a new standard of care for previously treated, advanced KRAS G12C-mutated NSCLC.

Cancer Cell

The algorithm is strongly aligned with contemporary NSCLC practice by stratifying testing by stage, conserving tissue, favoring broad DNA plus RNA profiling, and treating negative plasma results as no...

Brain metastases (BrMs) in non-small cell lung cancer (NSCLC) respond poorly to anti-PD-1 monotherapy, but the underlying immune resistance remains incompletely defined. Here we integrate clinical outcome analyses, paired human tissue profiling and syngeneic mouse models to characterize the BrM immune microenvironment. Clinical analyses suggest improved intracranial disease control with nivolumab plus ipilimumab compared with nivolumab alone. Paired human specimens show that BrMs contain fewer cytotoxic T lymphocytes (CTLs) and tertiary lymphoid structures (TLSs) than primary tumors, defining an immune-excluded phenotype. A syngeneic BrM model recapitulates this phenotype and resists anti-PD-1 monotherapy, whereas combined anti-PD-1 and anti-CTLA-4 blockade suppresses tumor growth and prolongs survival. Single-cell RNA sequencing, flow cytometry and immunofluorescence show increased CTL infiltration and effector function after combination therapy. CD8+ T cell depletion abrogates therap

Phase 3 final analysis of perioperative toripalimab in resectable stage II-III NSCLC showed a 34% reduction in death risk at nearly four years of

Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.

Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.

iOnctura is set to present critical findings regarding roginolisib in treating immunotherapy-resistant NSCLC at SITC 2026, highlighting its innovative approach.

RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.

Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the established biomarkers for predicting outcomes after such treatments.

Savolitinib is an oral, potent, highly selective MET–tyrosine kinase inhibitor (TKI). Combination therapy with savolitinib and osimertinib, an epidermal growth factor receptor (EGFR)–TKI, has shown...

Divarasib, a next-generation, oral KRAS G12C inhibitor, is more potent and selective in vitro than the first-generation KRAS G12C inhibitors sotorasib and adagrasib. In this phase 3, international,...

No description available